CN105998088B - 乌灵菌粉在制备用于防治骨质疏松症、骨坏死药物或保健食品中的应用 - Google Patents
乌灵菌粉在制备用于防治骨质疏松症、骨坏死药物或保健食品中的应用 Download PDFInfo
- Publication number
- CN105998088B CN105998088B CN201610584187.3A CN201610584187A CN105998088B CN 105998088 B CN105998088 B CN 105998088B CN 201610584187 A CN201610584187 A CN 201610584187A CN 105998088 B CN105998088 B CN 105998088B
- Authority
- CN
- China
- Prior art keywords
- wuling
- osteoporosis
- bone
- osteonecrosis
- bacteria powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000009137 wuling Substances 0.000 title claims abstract description 78
- 239000000843 powder Substances 0.000 title claims abstract description 70
- 241000894006 Bacteria Species 0.000 title claims abstract description 69
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 60
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 206010031264 Osteonecrosis Diseases 0.000 title claims abstract description 43
- 229940079593 drug Drugs 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 235000013402 health food Nutrition 0.000 title abstract description 5
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 83
- 206010028851 Necrosis Diseases 0.000 claims abstract description 30
- 230000017074 necrotic cell death Effects 0.000 claims abstract description 30
- 239000011575 calcium Substances 0.000 claims abstract description 11
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 8
- 150000003431 steroids Chemical class 0.000 claims abstract description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 239000002775 capsule Substances 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 210000002391 femur head Anatomy 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 102000055006 Calcitonin Human genes 0.000 claims description 4
- 108060001064 Calcitonin Proteins 0.000 claims description 4
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 4
- 229960004015 calcitonin Drugs 0.000 claims description 4
- 210000000629 knee joint Anatomy 0.000 claims description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 3
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 3
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 3
- 229930003316 Vitamin D Natural products 0.000 claims description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 208000018631 connective tissue disease Diseases 0.000 claims description 3
- 229940011871 estrogen Drugs 0.000 claims description 3
- 239000000262 estrogen Substances 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 239000000199 parathyroid hormone Substances 0.000 claims description 3
- 229960001319 parathyroid hormone Drugs 0.000 claims description 3
- 210000000323 shoulder joint Anatomy 0.000 claims description 3
- 159000000008 strontium salts Chemical group 0.000 claims description 3
- 239000011710 vitamin D Substances 0.000 claims description 3
- 235000019166 vitamin D Nutrition 0.000 claims description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 3
- 229940046008 vitamin d Drugs 0.000 claims description 3
- 230000003412 degenerative effect Effects 0.000 claims description 2
- XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical group OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 claims description 2
- 208000021864 drug-induced osteoporosis Diseases 0.000 claims description 2
- 210000002758 humerus Anatomy 0.000 claims description 2
- 210000001872 metatarsal bone Anatomy 0.000 claims description 2
- 210000000450 navicular bone Anatomy 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 208000001685 postmenopausal osteoporosis Diseases 0.000 claims description 2
- 210000003189 scaphoid bone Anatomy 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 210000004233 talus Anatomy 0.000 claims description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000004061 uncoupling agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 241001484259 Lacuna Species 0.000 abstract description 11
- 230000002829 reductive effect Effects 0.000 abstract description 9
- 208000007875 Femur Head Necrosis Diseases 0.000 abstract description 8
- 230000001476 alcoholic effect Effects 0.000 abstract description 8
- 238000011552 rat model Methods 0.000 abstract description 8
- 230000037182 bone density Effects 0.000 abstract description 6
- 230000008021 deposition Effects 0.000 abstract description 6
- 210000000689 upper leg Anatomy 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 5
- 238000009826 distribution Methods 0.000 abstract description 5
- 230000001413 cellular effect Effects 0.000 abstract description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract description 2
- 230000000857 drug effect Effects 0.000 abstract description 2
- 150000002596 lactones Chemical class 0.000 abstract description 2
- 239000011574 phosphorus Substances 0.000 abstract description 2
- 229910052698 phosphorus Inorganic materials 0.000 abstract description 2
- 210000003625 skull Anatomy 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 description 33
- 241000700159 Rattus Species 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 11
- 230000036407 pain Effects 0.000 description 11
- 238000003304 gavage Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 210000001624 hip Anatomy 0.000 description 6
- 229930002330 retinoic acid Natural products 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- MOVRKLZUVNCBIP-RFZYENFJSA-N cortancyl Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O MOVRKLZUVNCBIP-RFZYENFJSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000004394 hip joint Anatomy 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000004409 osteocyte Anatomy 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 206010036067 polydipsia Diseases 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- -1 1.5g/kg/d) Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010017577 Gait disturbance Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000037118 bone strength Effects 0.000 description 2
- 210000003321 cartilage cell Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000004349 growth plate Anatomy 0.000 description 2
- 239000009040 gushukang Substances 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000008338 local blood flow Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- QIMGSZURBOTPMW-UHFFFAOYSA-N 2-methoxy-5-(2,3,4-trimethoxyphenyl)cyclohepta-2,4,6-trien-1-one Chemical compound COC1=C(OC)C(OC)=CC=C1C1=CC=C(OC)C(=O)C=C1 QIMGSZURBOTPMW-UHFFFAOYSA-N 0.000 description 1
- CTERCLHSWSQHSD-UHFFFAOYSA-N 8-methoxypyrene-1,3,6-trisulfonic acid Chemical compound C1=C2C(OC)=CC(S(O)(=O)=O)=C(C=C3)C2=C2C3=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1 CTERCLHSWSQHSD-UHFFFAOYSA-N 0.000 description 1
- 206010001526 Air embolism Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010051728 Bone erosion Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000015813 Familial avascular necrosis of femoral head Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 1
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010058907 Spinal deformity Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 238000000184 acid digestion Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical class OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000000527 greater trochanter Anatomy 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000003694 hair properties Effects 0.000 description 1
- 208000021245 head disease Diseases 0.000 description 1
- 208000012285 hip pain Diseases 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000005056 memory consolidation Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000020097 white wine Nutrition 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
- 239000009750 xian ling gu bao Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610584187.3A CN105998088B (zh) | 2016-07-22 | 2016-07-22 | 乌灵菌粉在制备用于防治骨质疏松症、骨坏死药物或保健食品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610584187.3A CN105998088B (zh) | 2016-07-22 | 2016-07-22 | 乌灵菌粉在制备用于防治骨质疏松症、骨坏死药物或保健食品中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105998088A CN105998088A (zh) | 2016-10-12 |
CN105998088B true CN105998088B (zh) | 2018-11-20 |
Family
ID=57117491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610584187.3A Active CN105998088B (zh) | 2016-07-22 | 2016-07-22 | 乌灵菌粉在制备用于防治骨质疏松症、骨坏死药物或保健食品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105998088B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1843454A (zh) * | 2006-02-10 | 2006-10-11 | 浙江佐力药业股份有限公司 | 治疗妇女更年期综合症的药物制剂及其制备方法 |
CN102824375A (zh) * | 2012-09-18 | 2012-12-19 | 南京正亮医药科技有限公司 | 乌灵胶囊在制备抑制u251细胞增殖药物中的应用 |
-
2016
- 2016-07-22 CN CN201610584187.3A patent/CN105998088B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1843454A (zh) * | 2006-02-10 | 2006-10-11 | 浙江佐力药业股份有限公司 | 治疗妇女更年期综合症的药物制剂及其制备方法 |
CN102824375A (zh) * | 2012-09-18 | 2012-12-19 | 南京正亮医药科技有限公司 | 乌灵胶囊在制备抑制u251细胞增殖药物中的应用 |
Non-Patent Citations (2)
Title |
---|
乌灵菌粉的镇静作用及其机理研究;马志章等;《中国药学杂志》;19990608;第34卷(第06期);374-377 * |
药用真菌—乌灵参的研究现状概述;陈建等;《2006第六届中国药学会学术年会论文集》;20061101;4061-4065 * |
Also Published As
Publication number | Publication date |
---|---|
CN105998088A (zh) | 2016-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103142811A (zh) | 一种治疗原发性骨质疏松症的中药 | |
CN102526326B (zh) | 用于治疗绝经后骨质疏松症的中药及其制备方法 | |
CN104873624A (zh) | 一种用于痛风性关节炎的药物组合物 | |
CN104547750A (zh) | 一种治疗老年性骨质疏松症的中药组合物 | |
CN102579817A (zh) | 一种具有治疗骨质疏松功能的中药组合物 | |
CN102727711B (zh) | 一种治疗慢性疲劳综合症的中药 | |
CN1268370C (zh) | 补肾壮阳胶囊 | |
CN104013817A (zh) | 一种参竹精制剂及其制备方法 | |
CN103405755A (zh) | 一种治疗原发性骨质疏松症的药物组合物 | |
CN105998088B (zh) | 乌灵菌粉在制备用于防治骨质疏松症、骨坏死药物或保健食品中的应用 | |
CN105055863B (zh) | 一种中药组合物在制备用于治疗骨质疏松、骨坏死的药物或保健品中的应用 | |
CN101991757B (zh) | 一种补肾助阳的中药组合物及其制备方法 | |
CN109758559A (zh) | 一种治疗慢性疲劳综合征的中药组合物及其制备方法和应用 | |
CN104826095B (zh) | 一种软骨素联产蛋白粉及其生产方法和应用 | |
CN114558088B (zh) | 一种治疗原发性骨质疏松症的蒙药复方及其应用 | |
CN102727730B (zh) | 治疗男性不育的复方中药制剂及其制备方法 | |
CN107213223A (zh) | 一种用于治疗腰椎间盘突出症、骨质增生症的药物 | |
CN107951999A (zh) | 一种防治老年痴呆中药组合物及其制备方法 | |
CN100571722C (zh) | 治疗肾虚及更年期综合症的药物组合物及其制备方法 | |
CN103301195A (zh) | 一种治疗骨质疏松症的中药组合物及其制备方法 | |
CN1323628A (zh) | 一种补肾壮阳的中药制剂 | |
CN115381896A (zh) | 一种用于治疗骨质疏松症的中药组合物及其制备方法 | |
CN104758503B (zh) | 一种促进骨折愈合的组合物及其水煎液的制备方法 | |
CN111249367A (zh) | 一种用于骨质疏松、骨坏死和生骨活血的中药制剂及其制备方法 | |
CN117064958A (zh) | 一种用于骨折后康复期患者提高生存质量的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 215009 Suzhou high tech Zone, Jiangsu, No. 86 Applicant after: LEIYUNSHANG PHARMACEUTICAL GROUP Co.,Ltd. Address before: 215009 Suzhou high tech Zone, Jiangsu, No. 86 Applicant before: Lei Yun Shang Pharmaceutical Co.,Ltd. |
|
COR | Change of bibliographic data | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of Wuling mushroom powder in preparation of medicine or health food for prevention and treatment of osteoporosis and osteonecrosis Effective date of registration: 20221019 Granted publication date: 20181120 Pledgee: Shanghai Bank Co.,Ltd. Suzhou Branch Pledgor: LEIYUNSHANG PHARMACEUTICAL GROUP Co.,Ltd. Registration number: Y2022320010593 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |